Advertisements

Deflazacort Stada

Quick links to important sections

Deflazacort Stada

Advertisements
Advertisements

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Deflazacort Stada

Quick Facts

Property Description
Active Ingredient Deflazacort
Form Oral tablet, Oral suspension
Pharmacological Class Glucocorticoid (Synthetic Corticosteroid)
General Purpose Anti-inflammatory and Immunosuppressant
Origin Synthetic (Prodrug)

What Type of Medicine is Deflazacort Stada? (Identity and Class)

Deflazacort Stada is a prescription-only medication that contains the active ingredient Deflazacort, which is a synthetic corticosteroid belonging to the Glucocorticoid pharmacological class. This class of steroid hormones is designed to powerfully regulate the body's inflammatory and immune responses. Deflazacort is structurally derived from Prednisolone, distinguishing it from older glucocorticoids through chemical modification. It is recognized in clinical practice for its potent control over chronic, excessive inflammation. As a single-ingredient product, it is an essential systemic agent intended for oral administration to manage conditions where profound control of inflammation or immune activity is required.

Composition and Form: The Deflazacort Prodrug

The key component in Deflazacort Stada is the active substance Deflazacort, which is an inactive prodrug. This means the molecule must undergo rapid metabolism in the body to yield its primary and highly potent therapeutic agent: 21-desacetyldeflazacort (21-desDFZ). The resulting metabolite is the entity responsible for binding to the glucocorticoid receptors. This activation process ensures the compound's therapeutic effect is delivered systemically. The medication is available in two distinct dosage form options: a solid oral tablet and a liquid oral suspension, with the latter often favored for patients, particularly children, who may struggle with swallowing solid medications.

General Purpose: Anti-inflammatory and Immunosuppressant

The general purpose of the Deflazacort compound is rooted in its powerful dual action as a potent anti-inflammatory agent and an immunosuppressant. This function is critical for broadly modulating the entire immune system and suppressing the release of damaging pro-inflammatory signals. The core benefit is providing comprehensive systemic control over chronic inflammatory processes and reducing harmful immune overactivity. Its primary function is to decrease inflammation in the body.

Advertisements

What side effects are possible with Deflazacort Stada?

Possible side effects and safety information

Deflazacort, a systemic glucocorticoid, has an officially documented safety profile characterized by effects across multiple body systems, which are typically associated with the medicine's pharmacological class. The adverse reactions are classified by frequency based on clinical and regulatory data.


Frequency-Classified Adverse Reactions

Classification Examples (Organ Systems Affected)
Very Common (10%) Cushingoid appearance, increased appetite, weight gain, upper respiratory tract infection, central obesity, and hirsutism (Endocrine/Metabolic, Infections).
Common (mathbf1% to mathbf10%) Irritability, abnormal behavior, mood swings, headache, constipation, and abdominal pain (Psychiatric, Gastrointestinal, Nervous System).

Serious Safety Characteristics

Regulatory documents emphasize specific high-consequence safety risks. HPA axis suppression and subsequent acute adrenal insufficiency are key concerns, particularly upon abrupt cessation of treatment, as noted in official labeling. The medicine may increase susceptibility to severe infections and can cause reactivation of latent infections, due to its immunosuppressant properties. Rare but documented serious events include gastrointestinal perforation and thromboembolic events.


Population and Duration-Related Safety Notes

The risk profile is strongly tied to the duration of exposure. Chronic or prolonged use is officially associated with the increased incidence of osteoporosis, glaucoma, and posterior subcapsular cataracts. For the pediatric population, long-term use has the potential to suppress normal growth and development. Deflazacort is contraindicated in patients with known hypersensitivity to the active substance or excipients, and regulatory restrictions advise against concurrent administration of live or live-attenuated vaccines.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Deflazacort focuses on mandated emergency actions and the physiological consequences of excessive systemic exposure. Specific acute intoxication symptoms are not frequently documented in official labeling.

Overdose Scope Official Regulatory Statement
Documented physiological risk The primary concern from prolonged, high-dose exposure is the serious physiological outcome of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression.
Emergency-response statement Seek emergency medical attention immediately. Contact a poison control center or emergency services if severe symptoms like trouble breathing, collapse, or a seizure are observed.
Overdose Classifications (High-Level) Official Regulatory Statement
Supportive management Treatment is restricted to symptomatic and supportive measures, as the prescribing information does not list a specific antidote.
Monitoring requirement Professional monitoring for HPA axis suppression and potential Cushing's syndrome effects is required following periods of chronic excessive exposure.

Official overdose statements:

  • Regulatory guidance mandates that emergency medical care must be sought immediately when an overdose is suspected.
  • Management of exposure is strictly defined as symptomatic and supportive treatment, given that no specific reversal agent is known.
  • Overdose risk is formally assessed based on the potential for HPA axis suppression following chronic, high-dose ingestion.

Connection to the overall overdose profile: Regulatory documents define the Deflazacort overdose profile by emphasizing the critical requirement for immediate emergency care. The official statements prioritize the risk of HPA axis suppression—the central severe physiological consequence documented following excessive systemic exposure. This profile strictly guides users on when external medical help is required, as written in government labeling.

Advertisements

Therapeutic Uses of Deflazacort Stada

What Deflazacort Stada Treats: Main Uses and Benefits

Deflazacort is commonly used to help with conditions characterized by systemic imbalance and significant inflammatory activity. In its primary applications, the medication may assist with supporting muscle strength and functional capability in progressive disorders like Duchenne Muscular Dystrophy (DMD).

It is applied across domains where additional symptomatic support is needed, addressing symptoms related to inflammatory or irritative states in chronic conditions such as Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis, and certain types of Juvenile Chronic Arthritis. Furthermore, it is considered relevant in specialized settings for managing the immune response following an organ transplant and during acute symptomatic episodes like severe allergic reactions or flare-ups of chronic diseases.

It contributes to improved comfort during periods of heightened symptoms and helps patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Systemic Inflammation

The medication is relevant for managing symptoms associated with immune-mediated conditions, supporting the easing of symptoms related to inflammatory or irritative states, such as chronic swelling and pain.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Deflazacort Stada is strictly contraindicated for specific populations as documented in official regulatory labeling. Use is prohibited for patients with a known hypersensitivity to the drug or any of its components. It must also not be used by individuals with existing systemic fungal infections that are not currently treated with appropriate anti-infective therapy. Additionally, regulatory guidelines prohibit concurrent use with live or live-attenuated vaccines.

Age and Conditional Restrictions

For the medicine’s approved use, eligibility is established for patients 2 years of age and older. Safety and efficacy have not been established in children younger than 2 years of age.

Use during pregnancy and lactation is generally not recommended; it is restricted to situations where the potential benefit is judged to outweigh the documented risks. Patients with severe hepatic impairment are restricted from use because safety and optimal dosage have not been established in this population. Use requires specific caution in individuals with conditions such as ocular herpes simplex.

Advertisements

What should I know about interactions with other medicines?

Interaction scope

The interaction profile of deflazacort is defined by pharmacokinetic and pharmacodynamic mechanisms documented in regulatory materials. The primary pharmacokinetic interaction involves the CYP3A4 enzyme system, which metabolizes the active component, 21-desDFZ. Interacting product categories include CYP3A4 Inhibitors (Strong or Moderate), CYP3A4 Inducers (Strong or Moderate), Non-Steroidal Anti-inflammatory Drugs (NSAIDs), and Potassium-Depleting Diuretics.

Interaction classifications (high-level)

Interactions are classified as clinically significant, ranging from combinations that are formally prohibited to those requiring monitoring due to modified systemic exposure. Regulatory documents cite both pharmacokinetic interaction (metabolism) and pharmacodynamic interaction (additive effects). A notable restriction is the prohibition of Grapefruit Juice due to its CYP3A4 inhibitory action, which increases the plasma concentration of the active metabolite.

Resulting interaction structure

Official interaction statements specify that co-administration with strong or moderate CYP3A4 Inhibitors is expected to increase systemic exposure to the active metabolite, while CYP3A4 Inducers are expected to decrease exposure, potentially reducing efficacy. Pharmacodynamic effects include an increased risk of gastrointestinal ulcers when used with NSAIDs, and the enhanced hypokalaemic action when combined with Potassium-Depleting Diuretics. Furthermore, Live or Live-Attenuated Vaccines are prohibited during immunosuppressive doses, with official timing rules requiring separation of at least four to six weeks prior to starting treatment.

Advertisements

Mechanism of Action

Deflazacort Stada's mechanism is driven by its active metabolite, 21-desacetyldeflazacort (21-desDFZ), a full agonist at the intracellular Glucocorticoid Receptor (GR). This activated complex translocates into the cell nucleus, where it alters gene expression through two main actions: Transactivation and Transrepression.

Transactivation involves the complex binding to DNA, upregulating genes that produce anti-inflammatory proteins, such as Annexin-A1. Transrepression involves the complex directly interfering with and downregulating pro-inflammatory transcription factors like NF-κB, thereby decreasing gene transcription related to inflammation.

This molecular reprogramming initiates a systemic reduction of the entire cytokine cascade. Furthermore, the mechanism indirectly blocks the Eicosanoid Synthesis Pathway by inhibiting the enzyme Phospholipase A2 (PLA2). This combined molecular and enzymatic action suppresses the activity and migration of immune cells, including lymphocytes and monocytes, which provides the systemic modulation required to reduce immune and inflammatory activity.

This level of agonism necessarily engages the Hypothalamic-Pituitary-Adrenal (HPA) axis, leading to the physiological suppression of the body's natural cortisol production.

Advertisements

Dosage and Administration Information

How to Use Deflazacort Stada

This section outlines the general principles for using Deflazacort, focusing strictly on administration and dosing patterns.


Administration Scope

Feature Detail
Route of Administration Deflazacort is administered exclusively by the oral route, available in both tablet and liquid suspension forms.
Dosing Schedule The standard regimen for Duchenne Muscular Dystrophy (DMD) is calculated based on weight, typically 0.9 mg/kg once daily. For other conditions, adult maintenance doses generally range from 3 mg to 18 mg per day.
Frequency The total calculated dose is administered once daily.
Timing with Meals The medication can be taken with or without food.

Contextual Use and Discontinuation

Preparation and Intake: Tablets may be swallowed whole or crushed and mixed with a small amount of applesauce for immediate intake. The oral suspension must be shaken well before measuring and should be administered using the provided dispensing device for accurate dosing. The suspension can be mixed into milk or non-grapefruit juice.

Dose Adjustments: No dose adjustment is required for patients with any degree of kidney impairment or mild-to-moderate liver impairment. However, if Deflazacort is taken concurrently with a strong or moderate CYP3A4 inhibitor, the dose must be reduced to one-third of the recommended amount.

Course Management: If the medication has been used for more than a few days, the dose must be gradually reduced (tapered) before discontinuing to safely complete the course of therapy.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Clinical research on deflazacort has primarily focused on its use in Duchenne Muscular Dystrophy (DMD). The medication, a corticosteroid, is approved for this indication by major regulatory bodies in several countries.

Primary Trial Findings

The effectiveness of deflazacort was evaluated in randomized, placebo-controlled clinical trials involving male pediatric patients with DMD. The primary study compared two doses of deflazacort and an active comparator against a placebo group over a 12-week period.

  • Outcome Measured: Efficacy was measured by assessing the change in average muscle strength across multiple muscle groups using a standardized clinical assessment tool.
  • Results Documented: After 12 weeks of treatment, the group receiving deflazacort demonstrated a statistically significant change in muscle strength assessment scores compared to the placebo group. Follow-up data showed that a stability in average muscle strength was generally maintained in the deflazacort-treated patients through the end of the study (up to 52 weeks).

Comparative and Safety Profile

Comparative analyses of trial data have been conducted to assess deflazacort against other corticosteroids used in DMD. A meta-analysis indicated that patients treated with deflazacort experienced a lower rate of weight gain compared to those treated with prednisone. However, data from clinical trials suggest that deflazacort may be associated with an increased incidence of cataracts compared to prednisone.

Adverse Events Reported in Trials

Adverse events reported in clinical trials involving deflazacort are similar to those associated with other corticosteroids. The most common events documented in the primary clinical study (occurring in 5% or more of patients) included:

System Organ Class Common Reported Adverse Events
Appearance Facial puffiness (Cushingoid appearance), increased weight
Metabolic/GI Increased appetite, central obesity
Infection Upper respiratory tract infection, common cold
Urinary Frequent daytime urination
Skin/Hair Unwanted hair growth (hirsutism)

It is important to note that the full range of potential long-term risks is explored in ongoing post-marketing surveillance.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Deflazacort Stada (FAQ)


Q: What is the difference between Deflazacort and other steroids like Prednisone?

Deflazacort is a corticosteroid, a class of medicine that includes prednisone. Official clinical data comparing the two suggest that deflazacort may be associated with a lower rate of weight gain compared to prednisone. However, studies also indicated a potential for an increased incidence of cataracts with deflazacort compared to prednisone.


Q: Is Deflazacort Stada used for pain relief?

Deflazacort is classified as an anti-inflammatory and immunosuppressant medication. Its primary function is to decrease inflammation in the body. While reducing inflammation can help relieve pain, official indications are for specific conditions where controlling inflammation is the main therapeutic goal.


Q: Can Deflazacort Stada affect sleep?

Regulatory documents list central nervous system and psychiatric effects as adverse events that may occur. These can include irritability, mood swings, and a general classification of sleep disorders. Patients should be aware of these potential effects on their resting patterns.


Q: Does Deflazacort Stada affect blood sugar levels?

Yes, regulatory warnings indicate that corticosteroids can increase blood glucose levels, a condition known as hyperglycemia. This effect may worsen pre-existing diabetes. Regulatory guidance notes that the monitoring of blood sugar levels may be recommended during treatment.


Q: Is there a risk of addiction with Deflazacort Stada?

Deflazacort is not classified by regulatory documents as an addictive substance. However, abruptly stopping the medicine after extended use is strongly discouraged because it can suppress the body's natural production of steroids. This can lead to acute adrenal insufficiency or a 'withdrawal syndrome' that requires medical management.


Q: Can Deflazacort Stada be used while breastfeeding?

Use during breastfeeding is generally not recommended by official product information. Systemic corticosteroids like deflazacort are known to pass into human milk and could potentially affect an infant's growth or their own natural steroid production.


Q: What is the maximum duration people typically use Deflazacort Stada for?

The duration of treatment is determined by the condition being treated and is not fixed. Regulatory documents emphasize that chronic, long-term use (over many months or years) of any glucocorticoid is associated with an increased risk of specific adverse effects. Therefore, the goal is always to use the lowest effective dose for the shortest period possible.


Q: Can elderly people use Deflazacort Stada?

Official information does not contain specific restrictions or contraindications based only on advanced age. However, caution is generally advised for conditions that are more common in the elderly, such as osteoporosis and high blood pressure, due to the systemic nature of the drug.


Q: Is Deflazacort Stada the same as Deflazacort tablets from other brands?

Deflazacort is the active ingredient in all forms of this medication. Regulatory agencies approve generic versions, which are required to contain the same active ingredient and be bioequivalent to the branded product. Deflazacort Stada is simply one specific branded version.


Q: Is Deflazacort Stada used for autoimmune diseases?

As a potent corticosteroid, deflazacort has broad anti-inflammatory and immunosuppressive effects. In addition to its primary approved use, the European product information indicates that it is used to treat a wide range of conditions that require glucocorticoid therapy, including some autoimmune and inflammatory disorders.


Q: Does taking Deflazacort Stada require routine medical monitoring?

Yes, regulatory documents recommend regular monitoring for patients on long-term corticosteroid treatment due to the risk of serious side effects. This monitoring may involve checks for bone mineral density, vision (for cataracts or glaucoma), and blood glucose levels.


Q: Will Deflazacort Stada affect my ability to drive or operate machinery?

Official product information advises caution. Some reported side effects, such as mood disturbances, confusion, or dizziness, may potentially affect a person's ability to drive or use complex machinery. No specific prohibition is mandated.


Q: What should I do if I think I'm having an allergic reaction to Deflazacort Stada?

Regulatory guidance describes severe allergic reactions, such as hives, difficulty breathing, or swelling of the face or throat, as conditions that require immediate medical attention.


Q: What types of infections should be avoided while on Deflazacort Stada?

Because deflazacort suppresses the immune system, regulatory warnings caution against exposure to specific viral infections, such as chickenpox or measles. If a person is exposed to these infections, official guidance recommends they seek advice from their healthcare provider immediately.


Q: Can I take Deflazacort Stada if I have diabetes?

Regulatory guidance notes that deflazacort should be used with caution when a person has diabetes. Corticosteroids can raise blood sugar levels; therefore, monitoring blood glucose and potential adjustment of anti-diabetic medication is generally advised in regulatory information.


Q: Why does Deflazacort Stada have to be taken with food?

The official product labeling states that the medicine can be taken with or without food. However, taking the tablet with food may sometimes be suggested to help reduce the potential for gastrointestinal discomfort, a known side effect of corticosteroids.


Q: Is Deflazacort Stada used for asthma?

Official product information in some regions lists a broad range of conditions that may require glucocorticoid treatment. These indications include severe hypersensitivity reactions and acute asthma attacks.


Q: Does Deflazacort Stada have a generic version?

Yes, generic versions of deflazacort oral tablets and oral suspension have been approved by regulatory agencies. These products contain the same active ingredient and must meet the same standards for quality and bioequivalence.


Q: Does the brand name Stada make a difference?

Stada is the name of the company that manufactures and markets this specific product. The active and most important component is the ingredient deflazacort. The brand name indicates a specific version and formulation, but the active ingredient and the medicine's approved use are consistent with other deflazacort products.


Q: What is the risk of rebound after stopping Deflazacort Stada?

Stopping this medication requires a gradual reduction in dose (tapering) to prevent adrenal insufficiency. Abrupt cessation can result in a 'steroid withdrawal syndrome,' which may involve a non-specific collection of symptoms and a potential worsening of the underlying condition the medicine was treating.


Q: Can Deflazacort Stada be taken with blood pressure medication?

Official drug interaction statements caution that deflazacort may interact with certain blood pressure medications. Specifically, using it with potassium-depleting diuretics, such as thiazides, may increase the risk of developing low potassium levels (hypokalemia).


Q: What are the typical non-serious side effects people experience?

Based on regulatory data, common adverse reactions often reported include effects like facial puffiness, increased appetite, weight gain, unwanted hair growth (hirsutism), upper respiratory tract infection, and frequent daytime urination.


Q: Is it true that Deflazacort is sometimes called an 'oxazoline' steroid?

Yes. Official chemical descriptions and pharmacology literature identify deflazacort as a synthetic corticosteroid. It is structurally characterized by the presence of a methyl-oxazoline ring, which means it is often referred to as an oxazoline derivative of prednisolone.


Q: Is Deflazacort Stada available over the counter?

No. Deflazacort is a potent glucocorticoid that is classified as a prescription-only medicine (POM) in all major regulatory regions and requires a prescription from a licensed healthcare provider.

Advertisements

How should Deflazacort Stada be stored and disposed of?

Deflazacort must be stored according to regulatory specifications to ensure stability, which differ slightly between the tablet and oral suspension forms.

Storage & Disposal Constraint Official Regulatory Requirement
Storage Temperature Tablets: Store below 25 C. Oral Suspension: Store at controlled room temperature (20 C to 25 C). Keep the oral suspension from freezing.
Packaging Rule The tablets must be kept in the original container.
In-Use Stability Oral Suspension: Discard any unused product remaining 1 month after first opening the bottle.
Child Safety The medicine must be stored out of the sight and reach of children.
Disposal Instructions All unused or expired medicine must be disposed of according to local regulations for pharmaceutical waste; there are no special requirements for disposal of the tablet form.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deflazacort Stada found in:

A-Z Index: